Myanmar

Population 2018  54 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>181 (119–256)</td>
<td>338 (222–477)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>15 (10–22)</td>
<td>29 (19–41)</td>
</tr>
<tr>
<td>MDR/RR-TB incidenceºº</td>
<td>11 (7.4–16)</td>
<td>21 (14–30)</td>
</tr>
<tr>
<td>HIV-negative TB incidence</td>
<td>21 (12–31)</td>
<td>39 (23–58)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>3.7 (2.5–5.2)</td>
<td>6.9 (4.6–9.7)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases 4.9% (4.7–5.1)
- Previously treated cases 20% (19–21)

TB case notifications, 2018

- % tested with rapid diagnostics at time of diagnosis 42%
- % with known HIV status 89%
- % pulmonary 91%
- % bacteriologically confirmedººº 44%
- % children aged 0-14 years 19%
- % women 29%
- % men 52%

Total cases notified 139 518

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018 76% (54–120)
- TB patients facing catastrophic total costs, 2015 60% (56–63)
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 14% (8–22)

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance ººº 92%
- Previously treated cases 84%

Laboratory-confirmed cases* MDR/RR-TB: 3 479, XDR-TB: 35

Patients started on treatment* ** MDR/RR-TB: 2 650, XDR-TB: 29

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment 15%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 3.1% (2.8–3.4)

TB financing, 2019

- National TB budget (US$ millions) 62
- Funding source: 3% domestic, 60% international, 37% unfunded

*Ranges represent uncertainty intervals
º MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
ºº MDR/RR-TB: 3 479, XDR-TB: 35
ººº Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2019-10-18